Please assess the completion status of the following clinical trial:

Trial Title: Beta Cell Imaging in T1D Patients With a Different Glycemic Control

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Group 1 (stable glycemic control)~* Age ≥18 years~* T1D diagnosed ≥1 year at the start of the study~* HbA1c \<7 (\<53 mmol/mol)~* 17≤ BMI ≤30 kg/m2~* No severe hypoglycemic events in the past year and a maximum of 2 severe hypoglycemic events in their entire life.~* Intact hypoglycemic awareness~* Ability to sign informed consent~Group 2 (unstable glycemic control) Age ≥18 years~* T1D diagnosed ≥1 year at the start of the study~* HbA1c \>8.5 (\>69 mmol/mol)~* 17≤ BMI ≤30 kg/m2~* Minimum of 2 severe hypoglycemic events in the past year, or an impaired awareness of hypoglycemia (subjects may comply with both criteria, but this is not a requirement)~* Ability to sign informed consent~Exclusion Criteria:~* Previous treatment (within 6 months) with synthetic Exendin (Exenatide, Byetta®) or Dipeptidyl-Peptidase IV inhibitors~* Liver disease~* Renal disease~* Pregnancy or the wish to become pregnant within 6 months after the study~* Breastfeeding~* BMI \<17 kg/m2 or BMI \>30 kg/m2~* Age \<18 years~* Inability to sign informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Subjects with stable near-normal T1D (Type: None): * Mixed-meal tolerance test~* Intravenous injection with gallium-68-exendin followed by a PET/CT scan
- Subjects with unstable T1D (Type: None): * Mixed-meal tolerance test~* Intravenous injection with gallium-68-exendin followed by a PET/CT scan

Based on this trial design, predict the completion outcome and termination type (if applicable).